---
document_datetime: 2023-09-21 17:09:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/orphacol-epar-all-authorised-presentations_en.pdf
document_name: orphacol-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3631795
conversion_datetime: 2025-12-26 11:07:03.987584
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

EU/1/13/870/001

EU/1/13/870/002

EU/1/13/870/003

EU/1/13/870/004

EU/1/13/870/005

EU/1/13/870/006

Orphacol

Orphacol

Orphacol

Orphacol

Orphacol

Orphacol

50 mg

50 mg

50 mg

250 mg

250 mg

250 mg

Capsule, hard

Capsule, hard

Capsule, hard

Capsule, hard

Capsule, hard

Capsule, hard

Oral use

Oral use

Oral use

Oral use

Oral use

Oral use blister

(PVC/PVDC/alu)

blister

(PVC/PVDC/alu)

blister

(PVC/PVDC/alu)

blister

(PVC/PVDC/alu)

blister

(PVC/PVDC/alu)

blister

(PVC/PVDC/alu)

30 capsules

60 capsules

120 capsules

30 capsules

60 capsules

120 capsules